Vaccines: All things considered
1 Modeling and Simulation: Tool for Optimized Drug Development Martin Roessner Biostatistics sanofi aventis Bridgewater, NJ.
The Essentials of “Dosing Interval” Larry Goldkind M.D. Deputy Division Director, Division of Anti-Inflammatory, Analgesics, and Ophthalmic Drug Products.
Optimizing Medication Treatment in Children, Adolescents and Adults with ADHD
Treating Cancer
A Bayesian Industry Approach to Phase 1 Combination Trials in Oncology
2014-10-22 EUGM | ROYCHAUDHURI | Phase I Combination Trials
Mine...
Phase I dose escalation studies in Oncology: a call for on-study safety and flexibility Bill Mietlowski, Biometrics and Data Management, Novartis Oncology.
Adapting for Success: The Genesis of Adaptive Designs Andy Grieve SVP Clinical Trials Methodology, Innovation Centre, Aptiv Solutions. 1.
New Directions for Treatment in ALS Robert G. Miller, M.D. Forbes Norris MDA/ALS Research Center California Pacific Medical Center San Francisco, CA May.
REGULATION (EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014 on clinical trials on medicinal products for human use Overview.
